Increased expression levels of chromosomal AmpC β-lactamase in clinical escherichia coli isolates and their effect on susceptibility to extended-spectrum cephalosporins

Microbial Drug Resistance

Volumn 21, Issue 1, 2015, Pages 7-16

  Paltansing, Sunita ^a,d   Kraakman, Margriet ^a   Van Boxtel, Ria ^b   Kors, Ivo ^a   Wessels, Els ^a   Goessens, Wil ^c   Tommassen, Jan ^b   Bernards, Alexandra ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d IJSSELLAND HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; BETA LACTAMASE AMPC; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; ESCHERICHIA COLI PROTEIN; EXTENDED SPECTRUM BETA LACTAMASE; PORIN; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; OUTER MEMBRANE PROTEIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL MUTATION; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG HYDROLYSIS; ENZYME SYNTHESIS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; NONHUMAN; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WILD TYPE; BACTERIAL GENE; BIOSYNTHESIS; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

ESCHERICHIA COLI;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORINS; CHROMOSOMES, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; GENE EXPRESSION REGULATION, BACTERIAL; GENES, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, NUCLEIC ACID; SUBSTRATE SPECIFICITY;

EID: 84922558587     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2014.0108     Document Type: Article

References (30)

1. Antunes, N.T., H. Frase, M. Toth, S. Mobashery, and S.B. Vakulenko. 2011. Resistance to the third-generation cephalosporin ceftazidime by a deacylation-deficient mutant of the TEM b-lactamase by the uncommon covalenttrapping mechanism. Biochemistry 50:6387-6395.
2. Caroff, N., E. Espaze, D. Gautreau, H. Richet, and A. Reynaud. 2000. Analysis of the effects of-42 and-32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing ampC. J. Antimicrob. Chemother. 45: 783-788.
3. Chen, H.Y., and D.M. Livermore. 1993. Activity of cefepime and other b-lactam antibiotics against permeability mutants of Escherichia coli and Klebsiella pneumoniae. J. Antimicrob. Chemother. 32 Suppl B:63-74.
4. Clarke,B., M. Hiltz, H. Musgrave, andK.R. Forward. 2003. Cephamycin resistance in clinical isolates and laboratoryderived strains of Escherichia coli, Nova Scotia, Canada. Emerg. Infect. Dis. 9:1254-1259.
5. Clinical Laboratories Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; Seventeenth Informational Supplement. Clinical Laboratories Standards Institute, Wayne, PA, CLSI document M100-S17 [ISBN 1-56238-625-5].
6. Corvec, S., A. Prodhomme, C. Giraudeau, S. Dauvergne, A. Reynaud, and N. Caroff. 2004. Most Escherichia coli isolates overproducing chromosomal AmpC belong to phylogenetic group A. J. Antimicrob. Chemother. 60:872-876.
7. Forward, K.R., B.M. Willey, D.E. Low, A. McGeer, M.A. Kapala, M.M. Kapala, and L.L. Burrows. 2001. Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals. Diagn. Microbiol. Infect. Dis. 41:57-63.
8. Goessens, W.H., A.K. van der Bij, R. van Boxtel, J.D. Pitout, P. van Ulsen, D.C. Melles, and J. Tommassen. 2013. Antibiotic trapping by plasmid-encoded CMY-2 blactamase combined with reduced outer membrane permeability as a mechanism of carbapenem resistance in Escherichia coli. Antimicrob. Agents Chemother. 57:3941-3949.
9. Haldorsen, B., B. Aasnaes, K.H. Dahl, A.M. Hanssen, G.S. Simonsen, T.R. Walsh, A. Sundsfjord, and E.W. Lundblad. 2008. The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC. J. Antimicrob. Chemother. 62:694-702.
10. Hanson, N.D., and C.C. Sanders. 1999. Regulation of inducible AmpC b-lactamase expression among Enterobacteriaceae. Curr. Pharm. Des. 5:881-894.
11. Jacoby, G.A. 2009. AmpC b-lactamases. Clin. Microbiol. Rev. 22:161-182.
12. Jorgensen, R.L., J.B. Nielsen, A. Friis-Moller, H. Fjeldsoe-Nielsen, and K. Schonning. 2010. Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype. J. Antimicrob. Chemother. 65:460-464.
13. Kallman, O., C.G. Giske, O. Samuelsen, B. Wretlind,M. Kalin, and B. Olsson-Liljequist. 2009. Interplay of efflux, impermeability, andAmpC activity contributes to cefuroxime resistance in clinical, non-ESBL-producing isolates of Escherichia coli. Microb. Drug Resist. 15:91-95.
14. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
15. Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DDC(T)) method. Methods 25:402-408.
16. Mazzariol, A., G. Cornaglia, and H. Nikaido. 2000. Contributions of the AmpC b-lactamase and the AcrAB multidrug efflux system in intrinsic resistance of Escherichia coli K-12 to b-lactams. Antimicrob. Agents Chemother. 44:1387-1390.
17. Mulvey, M.R., E. Bryce, D.A. Boyd, M. Ofner-Agostini, A.M. Land, A.E. Simor, and S. Paton. 2005. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob. Agents Chemother. 49: 358-365.
18. Nelson, E.C., and B.G. Elisha. 1999. Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 43:957-959.
19. O Callaghan, C.H., A. Morris, S.M. Kirby, and A.H. Shingler. 1972. Novel method for detection of b-lactamases by using a chromogenic cephalosporin substrate. Antimicrob. Agents Chemother. 1:283-288.
20. Olsson, O., S. Bergstrom, F.P. Lindberg, and S. Normark. 1983. AmpC b-lactamase hyperproduction in Escherichia coli: natural ampicillin resistance generated by horizontal chromosomal DNA transfer from Shigella. Proc. Natl. Acad. Sci. U. S. A. 80:7556-7560.
21. Osborn, M.J., J.E. Gander, and E. Parisi. 1972. Mechanism of assembly of the outer membrane of Salmonella typhimurium. Site of synthesis of lipopolysaccharide. J. Biol. Chem. 247:3973-3986.
22. Oteo, J., M. Perez-Vazquez, and J. Campos. 2010. Extended-spectrum b-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr. Opin. Infect. Dis. 23:320-326.
23. Perez-Perez, F.J., and N.D. Hanson. 2002. Detection of plasmid-mediated AmpC b-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40: 2153-2162.
24. Peter-Getzlaff, S., S. Polsfuss, M. Poledica, M. Hombach, J. Giger, E.C. Bottger, R. Zbinden, and G.V. Bloemberg. 2011. Detection of AmpC b-lactamase in Escherichia coli: comparison of three phenotypic confirmation assays and genetic analysis. J. Clin. Microbiol. 49: 2924-2932.
25. Queenan, A.M., W. Shang, R. Flamm, and K. Bush. 2010. Hydrolysis and inhibition profiles of b-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob. Agents Chemother. 54:565-569.
26. Siu, L.K., P.L. Lu, J.Y. Chen, F.M. Lin, and S.C. Chang. 2003. High-level expression of ampC b-lactamase due to insertion of nucleotides between-10 and-35 promoter sequences in Escherichia coli clinical isolates: cases not responsive to extended-spectrum-cephalosporin treatment. Antimicrob. Agents Chemother. 47:2138-2144.
27. Then, R.L., and P. Angehrn. 1982. Trapping of nonhydrolyzable cephalosporins by cephalosporinases in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism. Antimicrob. Agents Chemother. 21:711-717.
28. Tommassen, J., H. van Tol, and B. Lugtenberg. 1983. The ultimate localization of an outer membrane protein of Escherichia coli K-12 is not determined by the signal sequence. EMBO J. 2:1275-1279.
29. Tracz, D.M., D.A. Boyd, R. Hizon, E. Bryce, A. McGeer, M. Ofner-Agostini, A.E. Simor, S. Paton, and M.R. Mulvey. 2007. AmpC gene expression in promoter mutants of cefoxitin-resistant Escherichia coli clinical isolates. FEMS Microbiol. Lett. 270:265-271.
30. Voulhoux, R., M.P. Bos, J. Geurtsen, M. Mols, and J. Tommassen. 2003. Role of a highly conserved bacterial protein in outer membrane protein assembly. Science 299:262-265.